Seneca Therapeutics, Inc. Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

Seneca Therapeutics, Inc. is a biotechnology research company based in Philadelphia, Pennsylvania. It was founded by Dr. Paul Hallenbeck to develop SVV-001, the Seneca Valley Virus, an oncolytic agent currently advancing in Phase I/II with a record of clinical safety in humans. SVV-001 targets cancer by binding to the TEM8 receptor, which is expressed in various solid tumors, including breast, lung, and neuroendocrine cancers, and the approach is also being explored as a viral vector for TEM8-targeted gene therapy.

As a smaller biotechnology firm, Seneca Therapeutics focuses on therapies designed to address difficult-to-treat solid cancers using virus-based modalities. Its work centers on leveraging TEM8 biology to develop therapies and potential gene-delivery constructs for TEM8-positive tumors.

Sign up for free to view info

Company overview Employee directory